rs786202225
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000051.4(ATM):c.478_482delTCTCA(p.Ser160AlafsTer23) variant causes a frameshift change. The variant allele was found at a frequency of 0.00000616 in 1,461,534 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000051.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.478_482delTCTCA | p.Ser160AlafsTer23 | frameshift_variant | Exon 5 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251342Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135846
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461534Hom.: 0 AF XY: 0.00000688 AC XY: 5AN XY: 727088
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:5
This sequence change creates a premature translational stop signal (p.Ser160Alafs*23) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 26270727). ClinVar contains an entry for this variant (Variation ID: 185501). For these reasons, this variant has been classified as Pathogenic. -
- -
Variant summary: ATM c.478_482delTCTCA (p.Ser160AlafsX23) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 4e-06 in 251342 control chromosomes. c.478_482delTCTCA has been reported in the literature as a presumably compound heterozygous genotype in at-least one individual with Ataxia-Telangiectasia and as a carrier genotype in an individual with breast cancer (example, Izatt_1999, Desmond_2015). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
- -
The following ACMG criteria is used: PVS1, PM2_Supporting (not reported in gnomAD), PM3_Supporting (detected in trans with a pathogenic variant). -
not provided Pathogenic:5
- -
DNA sequence analysis of the ATM gene demonstrated a five base pair deletion in exon 5, c.478_482del. This likely pathogenic sequence change results in an amino acid frameshift and creates a premature stop codon 22 amino acids downstream of the mutation, p.Ser160Alafs*23. This likely pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated ATM protein with potentially abnormal function. The p.Ser160Alafs23* change has been identified in a patient referred for genetic testing for hereditary breast and/or ovarian cancer (PMID: 26270727). The p.Ser160Alafs*23 change is reported in the gnomAD database in the heterozygous state in a single individual (dbSNP rs587780624). Truncating variants in the ATM gene have been observed in patients with breast cancer and in patients with ataxia. -
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (PMID: 26270727); Reported in the compound heterozygous state in a child with ataxia-telangiectasia (PMID: 30420857); Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 21933854, 10234507, 23726790, 31360874, 37715651, 31447099, 30420857, 26270727) -
ATM: PVS1, PM2, PS4:Supporting -
- -
Hereditary cancer-predisposing syndrome Pathogenic:3
The c.478_482delTCTCA pathogenic mutation, located in coding exon 4 of the ATM gene, results from a deletion of 5 nucleotides at nucleotide positions 478 to 482, causing a translational frameshift with a predicted alternate stop codon (p.S160Afs*23). This variant was reported in an individual with ataxia telangiectasia (A-T); a second ATM variant was not identified for this patient, but protein analysis showed severely reduced protein levels (Izatt L et al. Eur. J. Hum. Genet. 1999 Apr;7:310-20). This variant has also been identified in the homozygous state and/or in conjunction with other ATM variant(s) in individual(s) with features consistent with ataxia telangiectasia (Bakhtiar S et al. Front Immunol, 2018 Oct;9:2495). This variant was reported in 4/60466 breast cancer cases and in 0/53461 controls (Dorling et al. N Engl J Med. 2021 02;384:428-439). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
- -
This variant deletes 5 nucleotides in exon 5 of the ATM gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals suspected of hereditary breast or ovarian cancer and an individual with ataxia-telangiectasia in the literature (PMID: 10234507, 26270727). This variant has been identified in 1/251342 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Pathogenic:2
- -
PM2_Supporting+PVS1 -
Familial cancer of breast Pathogenic:2
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at